Search clinical trials for: BIBW 2992 medium dose

Total 484 results

Boehringer Ingelheim

Completed

Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States, Netherlands
Boehringer Ingelheim

Completed

Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors

Neoplasms
Boehringer Ingelheim

Completed

BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors

Neoplasms
Boehringer Ingelheim

Completed

Tolerability and Pharmacokinetics/-Dynamics of Single Rising Doses BIBT 986 BS in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab

Breast Neoplasms

United States, Brazil, Colombia, Peru
Boehringer Ingelheim

Completed

Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis

Pulmonary Fibrosis

Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czech Republic, France, Germany, Greece, Hungary, Ireland, Italy, Korea, Republic of, Mexico, Netherlands, Portugal, Russian Federation, South Africa, Spain, Taiwan and more
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Oral BIBP 5371 CL in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Efficacy and Safety of Oral Treatment With BIBF 1120 ES in Advanced Non-small-cell Lung Cancer

Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim

Completed

A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer

Prostatic Neoplasms
Boehringer Ingelheim

Completed

BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Adenocarcinoma | Carcinoma, Non-Small-Cell Lung

Hong Kong, Canada, Korea, Republic of, Belgium, Australia, United States, Taiwan, United Kingdom, Germany, Italy, Japan, Austria, Thailand, Peru, Ireland, Russian Federation, Philippines, France, Brazil, Chile, Argentina, Hungary, M... and more
Columbia University
Boehringer Ingelheim

Withdrawn

Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment

Esophageal Cancer | Gastrooesophageal Cancer | HER-2 Positive Gastric Cancer
Boehringer Ingelheim

Completed

Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.

Breast Neoplasms

United Kingdom
University of Chicago
National Cancer Institute (NCI)

Active, not recruiting

Afatinib in Advanced Refractory Urothelial Cancer

Recurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Ureter Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Recurrent Urethral Cancer | Stage III Urethral Cancer | Stage IV Urethral Cancer

United States
Boehringer Ingelheim

Completed

Multiple Oral Doses of BIBR 1048 MS Solution in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Study to Determine Tolerability After Intravenous Administration of BIBN 4096 BS in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Study to Determine Tolerability of Single Increasing Dose of BIBN 4096 BS in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics After Administration of Increasing Dose of BIBN 4096 BS in Healthy Male and Female Volunteers

Healthy
National Cancer Center, Korea
Boehringer Ingelheim

Completed

BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC

Non-small Cell Lung Cancer

Korea, Republic of
Gyroscope Therapeutics Limited
Novartis Pharmaceuticals

Active, not recruiting

HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

Dry Age-related Macular Degeneration

United States, Germany, United Kingdom, France, Spain, Australia, Poland
Emory University

Completed

Breath, Stress and Health: a Biocultural Study of Hatha Yoga Practice (Yoga)

Stress, Psychological | Stress, Physiological

India
Boehringer Ingelheim

Completed

Safety, Pharmacodynamics, and Pharmacokinetics of BIBT 1011 BS in Healthy Subjects

Healthy
University of Magdeburg
Boehringer Ingelheim

Terminated

BIBW 2992 (Afatinib) and Vinorelbine

Carcinoma Breast Stage IV

Germany
Boehringer Ingelheim

Completed

Single Rising Dose Tolerability Study of BIBN 4096 BS in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Inhalative Administration of BIBN 4096 BS in Healthy Male and Female Volunteers

Healthy
Merck Sharp & Dohme LLC

Completed

Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001)

Dengue
Alimorad Farshchian

Recruiting

Dose Escalation Pilot Study to Evaluate the Safety of Alocyte for the Treatment of Facetogenic Back Pain

Back Pain | Facet Joint Pain | Facet Joints; Degeneration

United States
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 207127 NA in Healthy Male Asian Volunteers and Single Dose Study of BI 207127 NA in Healthy Male Caucasian Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment

Breast Neoplasms

Korea, Republic of, Spain, Canada, Germany, Singapore, China, United Kingdom, Taiwan, Israel, United States, Australia, Slovenia, Italy, Brazil, India, Czechia, Netherlands, Ireland, Poland, Belarus, Belgium, Portugal, Russian Federation and more
Purdue University
Alliance for Potato Research and Education

Completed

Bioavailability of Potassium From Potatoes and Potassium Gluconate (Potato)

Blood Pressure | Potassium Bioavailability

United States
Peking University Third Hospital

Completed

The Efficacy and Safety of Sofadil for Injection in the Treatment of Acute Ischemic Stroke

Acute Ischemic Stroke

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Safety, Tolerability, and Efficacy Study of IBI314 in Patients With Mild to Moderate COVID-19

COVID-19

China
Danielle Kim Turgeon
PvP Biologics, Inc.

Terminated

Gastric Gluten-Degradation Activity of PvP001

Digestive System Disease

United States
Boehringer Ingelheim

Completed

BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type Psoriasis

Psoriasis
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

Systemic Lupus Erythematosus

Korea, Republic of, United States, Taiwan, China, Poland, Brazil, Argentina, Chile, Philippines, Australia, Colombia, Bulgaria, Mexico, Serbia, Greece, Spain, Israel, Japan, Mauritius, Moldova, Republic of, Romania, South Africa
AstraZeneca

Completed

MEDI7183 Phase 2 Study in Japanese Ulcerative Colitis Patients

Ulcerative Colitis

Japan
Kolon Life Science

Completed

Safety and Biological Efficacy Study of TisssueGene-C to Degenerative Arthritis

Degenerative Arthritis

Korea, Republic of
Danisco
Sprim Advanced Life Sciences

Terminated

Dose-Responsive Effect of Polydextrose on Whole Gut Transit Time (PDX-Transit)

Functional Constipation

Italy
Boehringer Ingelheim

Completed

BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)

Adenocarcinoma | Carcinoma, Non-Small-Cell Lung

China, Korea, Republic of, Thailand
Boehringer Ingelheim

Completed

BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer

Breast Neoplasms

France
Biocity Biopharmaceutics Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease

Diabetic Kidney Disease | IgA Nephropathy

China
University of California, Berkeley
University of California, Davis

Active, not recruiting

Moringa Powder Acceptability Trial Among Healthy Adults

Consumption | Side Effect | Acceptability

United States
Causeway Therapeutics

Completed

Safety, Tolerability, and Pharmacokinetics of Single Dose TenoMiR as a Treatment for Tennis Elbow

Tennis Elbow

United Kingdom
Boehringer Ingelheim

Completed

Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib

Carcinoma, Non-Small-Cell Lung

Spain
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Recruiting

The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

Systemic Lupus Erythematosus

United States, Spain, China, Korea, Republic of, Argentina, Bulgaria, Chile, Greece, Japan, Mauritius, Mexico, Moldova, Republic of, Poland, South Africa, Australia, Colombia, Philippines, Serbia
GlaxoSmithKline

Completed

GSK618334 Repeat Dose Study

Substance Dependence

United Kingdom
Glenmark Pharmaceuticals Ltd. India
Glenmark Pharmaceuticals S.A.

Withdrawn

A Clinical Trial to Study the Effects of GRC 17536 in Patients With Painful Diabetic Neuropathy (Painful Extremities Due to Peripheral Nerve Damage in Diabetic Patients)

Painful Diabetic Neuropathy

Germany, United Kingdom
Boehringer Ingelheim

Completed

Assessment of Safety, Pharmacokinetics and the Effect of BIBR 1048 MS on Coagulation Parameters in Healthy Volunteer Subjects

Healthy
Visterra, Inc.

Completed

Safety and Efficacy Study of VIS649 for IgA Nephropathy

Immunoglobulin A Nephropathy | Glomerular Disease | IgAN

United States, Australia, Canada, Hong Kong, India, Japan, Korea, Republic of, Malaysia, Philippines, Singapore, Spain, Sri Lanka, Taiwan, Thailand, United Kingdom
Johannes Gutenberg University Mainz

Terminated

BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer

Metastatic Disease

Germany
Centers for Disease Control and Prevention
International Centre for Diarrhoeal Disease Research, Bangladesh; World Health... and other collaborators

Enrolling by invitation

Assessing Immunogenicity of Intramuscular Sabin Inactivated Poliovirus Vaccine and Non-inferiority of Intradermal Fractional Inactivated Poliovirus Vaccine

Poliomyelitis

Bangladesh

Search clinical trials for: BIBW 2992 medium dose

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations